Note 13 - Segment Information

12 Months Ended

Jun. 30, 2023

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

Note 13. Segment Information

The basis for presenting segment results generally is consistent with overall Company reporting. The Company reports information about its operating segments in accordance with GAAP which establishes standards for reporting information about a company’s operating segments.

The Company has divided its operations into two reportable segments; Contract Manufacturing and Other Nutraceutical Businesses. The international sales, concentrated primarily in Europe, for the fiscal years ended June 30, 2023 and 2022 were $8,055 and $9,729, respectively.

Financial information relating to the fiscal years ended June 30, 2023 and 2022 operations by business segment are as follows:

		Sales, Net						Segment
		U.S.		International				Gross				Capital		Total
		Customers		Customers		Total		Profit		Depreciation		Expenditures		Assets
Contract Manufacturing	2023	$	40,230	$	8,047	$	48,277	$	3,630	$	348	$	109	$	19,507
	2022		44,450		9,641		54,091		5,917		332		486		19,061
Other Nutraceutical Businesses	2023		2,387		8		2,395		431		3		7		5,924
	2022		2,067		88		2,155		635		4		-		6,189
Total Company	2023		42,617		8,055		50,672		4,061		351		116		25,431
	2022		46,517		9,729		56,246		6,552		336		486		25,250